At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 114 enrolled
Drug / intervention
Vincristine +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NANT 2011- 01: Randomized Phase II Pick the Winner Study of 131I-MIBG, 131I-MIBG With Vincristine and Irinotecan, or 131I-MIBG With Vorinostat for Resistant/Relapsed Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium·interventional·Posted Jan 14, 2014·Updated Jun 8, 2022
In Brief
A Phase 2 clinical trial evaluating 131I-MIBG, Vincristine, and 2 other interventions for Neuroblastoma. Completed, enrolled 114 participants across 14 sites in 2 countries.
Detailed Summary
This study will compare three treatment regimens containing metaiodobenzylguanidine (MIBG) and compare their effects on tumor response and associated side effects, to determine if one therapy is better than the other for people diagnosed with relapsed or persistent neuroblastoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuroblastoma
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 2014
Enrollment StartJul 2014
Primary CompletionFeb 2021
TodayJul 2026
First PostedJan 14, 2014
Enrollment StartJul 1, 2014
Primary CompletionFeb 26, 2021
TodayJul 2, 2026
Enrollment to primary: 6.7 yearsPosted 12.5 years ago
Interventions
131I-MIBGradiation
Vincristinedrug
Irinotecandrug
Vorinostatdrug